Summary Seven patients with small volume ovarian carcinoma, remaining after conventional therapy with surgery and a platinum containing chemotherapy regimen, were treated with intraperitoneal monoclonal antibody guided radiotherapy. 100mCi'3' I conjugated to 10mg of monoclonal antibody were injected i.p. in 2,000ml peritoneal dialysis fluid. Patients were evaluated 3 months later; 3 had clinical progressive disease while third look laparotomy demonstrated progressive disease in 3 of the remaining 4 patients. The seventh patient did not have a third look laparotomy and is currently inevaluable for response.
Five patients with recurrent malignant ascites not controlled by diuretics or repeated paracentesis were similarly treated with 75-170 mCi13' I conjugated to 10mg monoclonal antibody. In three patients the ascites was controlled for a mean of 4 months. One patient died too early to assess the control of his ascites but tumour cells disappeared from the ascitic fluid after therapy. In the patient whose ascites was not controlled, a subpopulation of antigen-negative tumour cells was demonstrated. This study was unable to demonstrate a therapeutic benefit for i.p. injected monoclonal antibody guided radiotherapy for solid intraperitoneal tumour but suggests that it may be capable of controlling the accumulation of antigen positive malignant ascites.
Ovarian carcinoma is the most common cause of death from gynaecological cancer and the third most common of all cancers in women. In England and Wales, over 3,700 women die each year and 4,000 new cases are diagnosed (Toms et al., 1981) . The majority of patients with ovarian carcinoma, therefore, die of their disease. While mortality rates for carcinoma of the cervix and uterus have dropped over the last 30 years, the mortality rate for carcinoma of the ovary has risen (Osmond et al., 1983) .
The cornerstone of current therapy is surgery, as prognosis is most strongly related to volume of disease remaining after a debulking operation (Griffiths et al., 1979) . While high response rates to multidrug regimens have been reported (Slevin, 1986) , no improvement in long term survival has yet been achieved. Patients with ovarian cancer may continue to relapse and die of disease many years after achieving complete remission (Neijt et al., 1986) . When patients relapse after chemotherapy, the options are extremely limited. The emergence of chemoresistance in previously chemosensitive tumours has been well documented both in vivo (Friedlander et al., 1985) and in vitro (Wilson & Neal, 1981) and no long term benefit is available from further chemotherapy. The place of abdomino-pelvic radiotherapy at this point is also unclear (Dembo et al., 1979) . There is a clear need for further effective therapeutic modalities in this disease.
The success of monoclonal antibodies, labelled with a radioisotope, to detect ovarian cancer by immunoscintigraphy (Epenetos et al., 1982 (Epenetos et al., , 1985 Patiesky et al., 1985) , suggested that monoclonal antibody targetted therapy could be possible. However studies of antibody uptake by tumour after intravenous injection, suggested that insufficient discrimination between tumour and blood as well as low absolute levels of uptake occurred . Therefore, a regional, intraperitoneal approach to ovarian cancer seemed logical for many reasons. While over 80% of patients have disease outside the pelvis at presentation, over 75% have disease confined to the peritoneal cavity (Shepherd, 1985) . Large i.p./i.v. concentration advantages have been demonstrated when chemotherapy has been given intraperitoneally rather than intravenously (Myers & Collins, 1983) and it has been shown that i.p. injected albumin can penetrate tissue to a depth in excess of 1 cm (Dedrick, 1985 Early, empirical studies were encouraging, however, quantitative studies on the uptake of i.p. injected monoclonal antibodies into solid tumour and ascites were equivocal when solid tumour was considered (Hammersmith Oncol. Gp. & ICRF, 1984; Epenetos, 1986; .
Uptake of i.p. injected monoclonal antibody conjugates into solid tumour was shown to vary markedly both within and between patients, however, when ascites cells were considered, consistently greater uptake and large tumour cell: normal tissue or blood ratios were demonstrated Lawson et al., 1986) .
It was therefore decided to perform separate studies of i.p. 1311 monoclonal antibody therapy in patients with ovarian cancer, recurrent or persistent after conventional therapy, and in patients with recurrent malignant ascites which was not controlled by paracentesis and/or diuretics.
Materials and methods

Patients
Patients with ovarian cancer without ascites had failed conventional therapy consisting of radical debulking surgery and platinum containing chemotherapy. All patients were referred after second look laparotomy (Table I) where further debulking to less than two centimetres disease and full documentation of site and size of tumour nodules was carried out.
Patients referred for treatment of recurrent ascites were a heterogeneous group. All patients had reaccumulation of ascites within 6 weeks of paracentesis and, in all but 2 (Cases 9 and 12), despite spironolactone orally (Table II) .
Patients were treated after full informed consent had been obtained and these studies were approved, in advance, by the Antibodies used were produced in bulk by the Cell Production Unit, ICRF Clare Hall, purified by affinity chromatography on Protein A-Sepharose and stored, frozen in citrate buffer.
Iodination of antibodies
Antibodies were conjugated to 1311 by the N-bromosuccinimide method. This technique has been shown to reliably result in iodination efficiencies of 95% with no loss of antibody reactivity. Because of the high iodination efficiency, no separation of conjugate and free iodine was necessary. Antibody-radioiodine conjugates were used within 2h of synthesis as radiolysis of antibody has been demonstrated to occur by 20h . Activity of iodinated antibody ranged from 7-17mCimg-.
Demonstration of antigen expression
Solid tumour tissue, removed at laparotomy was examined by the indirect immunoperoxidase technique (Polak & Van Noorden, 1983) 
Delivery of antibody
Twenty-four hours prior to treatment, a thyroid blocking regimen of 120mg potassium iodide p.o. daily was begun and continued for 4 weeks.
In 4 patients treated after second look laparotomy, a Hickman cannula had been inserted into the peritoneal cavity at surgery and patency maintained by heparinized saline flushing. In the other patients, a 14 G Wallace IV Cannula was inserted, under sterile conditions under local anaesthetic, directly into the peritoneal cavity. Previous studies using this technique had demonstrated uniform peritoneal distribution of antibody conjugate as assessed by radioimmunoscintigraphy immediately after instillation .
Fifteen hundred ml of peritoneal dialysis fluid (CAPD2 -Frisenius, FRG) was instilled, the system tested for leaks and the abdomen examined for even distribution of fluid. In those patients with ascites, the ascites was drained over 4-96h prior to therapy and no further fluid instilled. It has been demonstrated that a volume of 1,500-2,000 ml is required to adequately distribute intraperitoneally injected substances (Dunnick et al., 1979) . The antibody was, therefore, then instilled in a further 500 ml fluid and the vial checked to ensure that all antibody was delivered.
At no time, either in the iodination procedure or the delivery need the radiolabel be handled unshielded.
Pharmacokinetics
Total body counts were made at 6 h, 18 h and then daily using a hand held dose rate meter and, when activity was sufficiently low, this was checked by formal whole body counting. Patients were allowed home after whole body activity was below 30mCi. A sample of blood was also drawn at these times and escape of activity into the blood assessed, assuming a blood volume of 80mg kg-1 (Ganong, 1985 In one patient (Patient 4), isolated tumour foci, noted at the previous laparotomy on the bowel serosa, were seen to have regressed, while new disease at the hepatic flexure had appeared. There was no overall benefit to the patient.
In Patient 2, a fine intraperitoneal adhesion reaction was seen, this patient subsequently developed small bowel obstruction which was managed conservatively. This was not seen in the other two patients at third look laparotomy. Treatment of recurrent ascites Patient 8 suffered no ill effects from treatment and his whole body activity had decreased sufficiently for him to be discharged home by 7 days after injection. By 4 weeks after discharge, his ascites had cleared completely on clinical examination, revealing large intra abdominal tumour masses which remained unchanged. In this period, his girth decreased from 107cm to 94cm, his appetite and level of activity increased and his ascites did not recur. He died with progressive solid masses in his abdomen four months after intraperitoneal therapy without recurrence of his ascites.
Patient 9 presented with a rapid onset ascites one month before intraperitoneal treatment. At laparotomy he had extensive disease (Stage IV), and his ascites recurred within 2 weeks of surgery. Nine litres of ascites fluid were removed in the 48 h prior to instillation of the conjugated antibody. Three days after antibody was instilled he became severely hypovoaemic with oliguria and hypotension. He was resuscitated by fluid replacement but complained of severe dysphagia preventing intake of all solids. Serum analysis and cardiac enzyme levels were normal, as was his ECG. Seven days after intraperitoneal treatment, a further hypovolaemic crisis occurred, from which he did not recover. Ascites removed at this time demonstrated complete absence of tumour cells. Complete drainage paracentesis was not performed on subsequent patients.
Patient 10 had recurrent ascites from carcinoma of the ovary previously treated with intensive chemotherapy (high dose cyclophosphamide and cisplatin). Both her primary tumour and ascites cells expressed the HMFG2 antigen and this antibody was used for therapy. Seven hours after injection of the antibody, ascites were withdrawn and autoradiography of the cell pellet demonstrated specific uptake of isotope by tumour cells. Some clumps of tumour cells, however, were free of activity (Figure 3) . Her ascites did not resolve and a further ascites sample taken at 18 days after injection showed numerous tumour cells which were HMFG2 negative (Figure 4) Three patients (Patients 9, 10, 11) suffered from dysphagia beginning 3-4 days after therapy. In Patients 9 and 10, this was severe and not relieved by antacid and H2 blockers. An hiatus hernia was demonstrated radiologically in Patient 10 but no cause was found in Patient 9 before he died of disease.
The majority of patients complained of nausea and 'feeling unwell' for 36h after antibody injection, but no treatment was required, no vomiting occurred and all symptoms spontaneously resolved.
Pharmacokinetics of the injected radioisotope were analysed separately in the two groups. Ovarian cancer patients without ascites Following injection, whole body activity declined exponentially with a half life of 34h. Maximum blood levels were 18+5% total activity and were seen at 60 h (Figure 5a ).
Patients with malignant ascites In these patients, whole body activity also declined exponentially, with a mean half life of 50 h. Maximum blood levels were 6 + 1% total activity and these were seen at 40-80 h ( Figure Sb) .
Discussion
In this study, 7 patients with small volume, recurrent ovarian carcinoma were treated with HMFG2 conjugated 1311. All patients' tumours were shown to express the HMFG2 antigen. Although previous tracer dose studies (Anderson et al., 1974) or radioactive isotopes of phosphorus or gold (Ariel et al., 1966; Dybicki et al., 1959) will be needed.
In the patient whose treatment failed, a population of antigen negative cells which failed to localize the antibody conjugate was demonstrated. Epenetos (Personal communication) recently experienced a similar case, where the antigen negative cell population was shown to express an alternative tumour associated antigen and the patient was successfully retreated. In this instance, unfortunately, no such alternative tumour associated antigen expression was demonstrated. This case, however, does serve as an important negative control and demonstrates that the resolution of ascites seen in the other patients was dependent on the specific activity of the antibody. The rapid clearance of tumour cells from the ascites of Patient 9 would support this.
The death of Patient 9 was considered to be due to hypovolaemic shock related to fluid shifts from his large volume paracentesis and poor fluid intake at the time. He had no symptoms suggesting localized toxicity and the pharmacokinetic data provided by him did not differ from his peers.
When the clearance of antibody conjugate from the body was investigated, it was seen that patients with malignant ascites had a much slower clearance of radioactivity than those with solid tumours. This was reflected in the maximum serum levels achieved and the time at which they occurred. These data suggest that the monoclonal antibody conjugate was being trapped by the high concentration of antigen present in the ascites and further supports the specific nature of this antitumour therapy.
There have been several case reports of successful radioimmunotherapy for solid intraperitoneal deposits described. However, these patients comprise the first series reported where all patients were objectively evaluated using third look laparotomy if appropriate. Unfortunately, the results have not demonstrated therapeutic efficacy for intraperitoneal monoclonal antibody guided therapy in the treatment of solid ovarian cancer deposits. For palliative treatment of malignant ascites, however, such monoclonal antibody therapy may have therapeutic potential.
